02-26-02

000#5

FEB 1 9 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Sessistant Commissioner for Patents, Washington, D.C. 20231-0001
The January 31, 2002

COPY OF PAPERS ORIGINALLY FILED

PERLEGEN SCIENCES, INC

y: Aurie Reisinger

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

COX, DAVID R. et al

Application No.: 10/042,819

Filed: January 7, 2002

For: GENETIC ANALYSIS SYSTEMS AND

METHODS

Examiner: TBD

Art Unit: TBD

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT UNDER 37 CFR §1.97 AND §1.98

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

The reference cited on the attached form PTO-1449 is being called to the attention of the Examiner. A copy of the reference listed is enclosed herewith.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the

Cox, D.R. et al

Application No.: 10/042,819

Page 2

PATENT Attorney Docket No.: 1016

Commissioner is authorized to charge such fee to Deposit Account No. 502043. Please

charge any additional fees or credit any overpayment to the above-noted Deposit

Account.

Respectfully submitted,

Vern Norviel Reg. No. 32,483

Perlegen Sciences, Inc. 2021 Stierlin Court Mountain View, CA 94043

Tel: (650) 625-4577 Fax: (650) 625-4574



PTO/SB/42 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Over the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Sheet 1 of 1

INFORM		37 (E CITATIO	NI	Docket Nu 1016-N			Patent Number				
INFORMATION DISCLOSURE CITATION IN A PATENT										Applicant Cox, et al.						
(1							essary)		Issue Date			Group Art Unit				
 						-		U. S	. PA	TENT DOC	UMEN	ITS				
EXAMINER INITIAL	DOCUMENT NUMBER DATE									NAME CLASS			SUBCLASS	FILING DATE IF APPROPRIATE		
			_	_		_										
			_	_			\vdash									
	_		\dashv	_	_	_										
	<u></u>		1		<u></u>	l		FOREI	GN	PATENT D	OCUM	IENTS	<u></u>			
												SUBCLASS	Translation			
	DOCUMENT NUMBE						R	DATE		COUNTRY		CLASS	SUBCLASS	YES	NO	
						<u></u>										
								OTHER DO	CUI	MENTS (Inc	luding	Author, Title	, Date, Pertine	ent Pages, Et	(C.)	
•		_	1													
	Ì		Oestreicher, P., "4 th Annual Pharmacogenomics and Medicine Lectures" <i>Pharmacogenomics</i> . 2 (3):291-296 (2001).													
	_															
														· · · · · · · · · · · · · · · · · · ·		
EXAMINER										DATE CONSIDERED						

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PTO/SB/42 (10-96)